Chemotherapy for advanced ovarian cancer
58 results
1 - 58
Chemotherapy for advanced ovarian cancer- Chemotherapy for malignant germ cell ovarian cancer in adult patients with early stage, advanced and recurrent disease
- Neoadjuvant chemotherapy before surgery versus surgery followed by chemotherapy for initial treatment in advanced epithelial ovarian cancer
- Interval debulking surgery for advanced epithelial ovarian cancer
- Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer
- Maintenance chemotherapy for ovarian cancer
- Interferon after surgery for women with advanced (Stage II‐IV) epithelial ovarian cancer
- Cytoreductive surgery plus chemotherapy versus chemotherapy alone for recurrent epithelial ovarian cancer
- Impact of residual disease as a prognostic factor for survival in women with advanced epithelial ovarian cancer after primary surgery
- Topotecan for ovarian cancer
- Positron emission tomography (PET) and magnetic resonance imaging (MRI) for assessing tumour resectability in advanced epithelial ovarian/fallopian tube/primary peritoneal cancer
- Chemotherapy and/or radiotherapy in combination with surgery for ovarian carcinosarcoma
- Luteinising hormone releasing hormone (LHRH) agonists for the treatment of relapsed epithelial ovarian cancer
- Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer
- Weekly versus tri‐weekly paclitaxel with carboplatin for first‐line treatment in women with epithelial ovarian cancer
- Laparoscopy for diagnosing resectability of disease in women with advanced ovarian cancer: Cochrane systematic review (diagnostic test accuracy)
- Epidermal growth factor receptor blockers for the treatment of ovarian cancer
- Ultra‐radical (extensive) surgery versus standard surgery for the primary cytoreduction of advanced epithelial ovarian cancer
- Poly(ADP‐ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer
- Centralisation of services for gynaecological cancer
- Laparoscopy versus laparotomy for FIGO stage I ovarian cancer
- Optimal primary surgical treatment for advanced epithelial ovarian cancer
- Angiogenesis inhibitors for the treatment of epithelial ovarian cancer
- Interventions for the treatment of borderline ovarian tumours
- Effectiveness of tranexamic acid in reducing blood loss during cytoreductive surgery for advanced ovarian cancer
Gynaecological cancers 
Semuloparin reduces VTE in cancer patients but at high cost (SAVE-ONCO)- Surgical cytoreduction for recurrent epithelial ovarian cancer
- Exenterative surgery for recurrent gynaecological malignancies
- Antigen‐specific active immunotherapy for ovarian cancer
- Pegylated liposomal doxorubicin for first‐line treatment of epithelial ovarian cancer